Terms: = Endocrine gland cancer AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523 AND Staging
5 results:
1. [Comparison of radical antegrade modular pancreatosplenectomy with conventional distal pancreatectomy for pancreatic adenocarcinoma of the body and tail].
Yin J; Huang XM; Lu ZP; Zhang K; Wu PF; Xu D; Dai CC; Wu JL; Gao WT; Wei JS; Guo F; Chen JM; Jiang KR; Miao Y
Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):505-511. PubMed ID: 32610419
[No Abstract] [Full Text] [Related]
2. Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort.
Nava CF; Zanella AB; Scheffel RS; Maia AL; Dora JM
Arch Endocrinol Metab; 2019 Feb; 63(1):5-11. PubMed ID: 30864625
[TBL] [Abstract] [Full Text] [Related]
3. Pancreatic cancer: progress made.
Simianu VV; Zyromski NJ; Nakeeb A; Lillemoe KD
Acta Oncol; 2010 May; 49(4):407-17. PubMed ID: 20059311
[TBL] [Abstract] [Full Text] [Related]
4. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract] [Full Text] [Related]
5. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract] [Full Text] [Related]